Entrada Therapeutics (TRDA) Current Assets (2020 - 2026)

Entrada Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $266.9 million for Q1 2026.

• In Q1 2026, Current Assets fell 33.81% year-over-year to $266.9 million; the TTM figure through Mar 2026 stood at $266.9 million (down 33.81% YoY), while the FY2025 annual figure was $306.3 million, down 30.4% from the prior year.
• Current Assets was $266.9 million for Q1 2026 at Entrada Therapeutics, down from $306.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $489.5 million in Q2 2024 to a low of $209.9 million in Q4 2022.
• Historically, Current Assets has averaged $355.4 million across 5 years, with a median of $369.8 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Assets jumped 90.03% in 2022, then plunged 33.81% in 2026.
• A 5-year view of Current Assets shows it stood at $209.9 million in 2022, then soared by 76.19% to $369.8 million in 2023, then rose by 19.0% to $440.0 million in 2024, then sank by 30.4% to $306.3 million in 2025, then slipped by 12.86% to $266.9 million in 2026.
• The last three Current Assets figures came in at $266.9 million (Q1 2026), $306.3 million (Q4 2025), and $338.3 million (Q3 2025), per Business Quant data.